Skip to content

Amgen AMGN Operating Income

Operating Income at other companies

Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$642.9M+8.7%
Nektar Therapeutics logo
Nektar TherapeuticsNKTR
-$39.05M+12.3%
Oruka Therapeutics, Inc. logo
Oruka Therapeutics, Inc.ORKA
-$36.43M-45.2%
Rigel Pharmaceuticals logo
Rigel PharmaceuticalsRIGL
$11.89M-7.0%
Jazz Pharmaceuticals logo
Jazz PharmaceuticalsJAZZ
$336.6M+702%
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
-$34.64M-25.8%

Other financials

Income statement

See full
Revenue$8.6B+5.8%
Gross profit$5.9B+13.4%
Net income$1.8B+5.1%
EPS (diluted)$3.34+4.4%

Balance sheet

See full
Cash & equivalents$559.0M+10.0%
Total debt$57.3B-0.1%
Total equity$9.2B+48.1%
Total assets$92.5B+3.5%

Cash flow

See full
Operating cash flow$2.2B+57.4%
CapEx$712.0M+73.2%
Free cash flow$1.5B+50.7%

Valuation

See full
Market cap$190.42B+22.4%
Enterprise value$247.18B+16.4%
P/E24.4×-1.8×
P/S5.1×+0.6×

Profitability

See full
Gross margin68.3%+5.3pp
Operating margin28.4%+6.6pp
Net margin21%+3.6pp
FCF margin23.1%-8.9pp

Returns & leverage

See full
Return on equity101.3%-4.4pp
Debt / equity6.2×-3.0×
Current ratio1.3×+0.1×

Where this comes from

Reported directly by Amgen in its filing.

Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.

The official record: Amgen’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Amgen's operating income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Amgen's operating income?
Amgen (AMGN) reported operating income of $2.67B in Q1 2026.
How has Amgen's operating income changed year-over-year?
Amgen's operating income increased by 126.3% year-over-year, from $1.18B to $2.67B.
What is the long-term trend for Amgen's operating income?
Over 4 years (2021 to 2025), Amgen's operating income has grown at a 4.4% compound annual growth rate (CAGR), from $7.64B to $9.08B.
What does operating income mean?
Gross profit minus all operating expenses (SG&A, R&D, D&A). Measures the profit from core business operations before interest, taxes, and non-operating items.